UNASSIGNED: 185 Background: @entity1211 ( @entity1211 ) is a common complication for @entity5 @entity1 , leading to hospitalizations that increase the burden of @entity5 management. Our study aimed to estimate the incidence and costs of hospitalizations for @entity1211 , in French @entity1 with @entity0 ( @entity0 ), @entity694 ( @entity694 ), @entity5 (PC), four of the most frequent @entity5 in France. METHODS: We used the French national hospital database (PMSI) to select new @entity1 with @entity0 , @entity694 , LC or PC in 2010, who had at least one @entity1211 -related hospitalization during the following two years. @entity1211 -related stays and @entity1 were identified using the disease-specific ICD-10 codes. Hospital costs were calculated over stays for which @entity1211 was considered as primary/related diagnosis. Costs were estimated from the healthcare system perspective, using the French official tariffs. RESULTS: Among 194,964 @entity1 newly diagnosed in 2010 with @entity0 , @entity694 , LC or PC in 2010, 8,909 (4.6%) were hospitalized for a @entity1211 or experienced @entity1211 at hospital, representing, 12,880 hospital stays. During the two-year follow-up, 2,053 (23.0%) @entity1 were re-hospitalized for a @entity1211 recurrence, representing 3,969 stays (30.8% of admissions for @entity1211 ). For one @entity1 with @entity1211 who did not experience recurrence, the mean hospital cost over two years ranged from    3,302 to    3,674. This amount was dramatically increased for @entity1 with recurrent @entity1211 , as it ranged from    5,441 to    5,692 per @entity1 . Hospitalizations for @entity1211 associated with those 4 types of @entity5 only were responsible for an overall expenditure reaching    13.30 million over two years, including    1.82 million due to recurrent events. CONCLUSIONS: @entity1211 -related @entity5 hospitalizations remain frequent and induce a notable cost. Prevention and management in respect to guidelines would be an efficient way to reduce the incidence of this complication and moderate its economic cost. [Table: see text].

Incidence and costs of thromboembolic events in @entity5 @entity1 : A study on four major XXXX localization.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'BC'] @entity5 :: ('MESH:D009369', 'Disease') :: ['lung cancer (LC) or prostate cancer', 'cancers', 'cancer'] @entity694 :: ('MESH:D003110', 'Disease') :: ['colon cancer', 'CC'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['Venous thromboembolic event', 'VTE']
@entity5 :: (MESH:D009369,Disease) :: ['cancer']
